| Literature DB >> 19891865 |
Lin H Chen1, Mary E Wilson, Xiaohong Davis, Louis Loutan, Eli Schwartz, Jay Keystone, Devon Hale, Poh Lian Lim, Anne McCarthy, Effrossyni Gkrania-Klotsas, Patricia Schlagenhauf.
Abstract
Length of travel appears to be associated with health risks. GeoSentinel Surveillance Network data for 4,039 long-term travelers (trip duration >6 months) seen after travel during June 1, 1996, through December 31, 2008, were compared with data for 24,807 short-term travelers (trip duration <1 month). Long-term travelers traveled more often than short-term travelers for volunteer activities (39.7% vs. 7.0%) and business (25.2% vs. 13.8%). More long-term travelers were men (57.2% vs. 50.1%) and expatriates (54.0% vs. 8.9%); most had pretravel medical advice (70.3% vs. 48.9%). Per 1,000 travelers, long-term travelers more often experienced chronic diarrhea, giardiasis, Plasmodium falciparum and P. vivax malaria, irritable bowel syndrome (postinfectious), fatigue >1 month, eosinophilia, cutaneous leishmaniasis, schistosomiasis, and Entamoeba histolytica diarrhea. Areas of concern for long-term travelers were vector-borne diseases, contact-transmitted diseases, and psychological problems. Our results can help prioritize screening for and diagnosis of illness in long-term travelers and provide evidence-based pretravel advice.Entities:
Mesh:
Year: 2009 PMID: 19891865 PMCID: PMC2857257 DOI: 10.3201/eid1511.090945
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Flow chart for analysis of illness and injury in long-term travelers, GeoSentinel Surveillance Network, June 1996–December 2008.
Figure 2Proportionate illness (per 1,000 ill travelers) for the most frequent diagnoses in long-term travelers, by world geographic region visited, GeoSentinel Surveillance Network, June 1996–December 2008. PEP, postexposure prophylaxis; IBS, irritable bowel syndrome; TB, tuberculosis; LTBI, latent TB infection; CLM, cutaneous larva migrans; P., Plasmodium.
Most common diagnoses for long-term travelers (n = 4,742) seen after travel and proportionate illness compared with short-term travelers (n = 28,618), GeoSentinel Surveillance Network, June 1996–December 2008*
| Rank† | Diagnosis | Rate/1,000 travelers | Odds ratio (95% confidence interval) | ||||
|---|---|---|---|---|---|---|---|
| Overall | South America | Southeast Asia | Sub-Saharan Africa | All other regions | |||
| 1 | Diarrhea, chronic unknown | 50 | 1.20‡ (1.04–1.38) | 1.19 (0.81–1.75) | 1.59§ (1.05–2.39) | 0.92 (0.64–1.31) | 1.19 (0.99–1.44) |
| 2 | 36 | 1.57‡ (1.32–1.86) | 0.85 (0.49–1.47) | 1.48 (0.80–2.73) | 1.93‡ (1.39–2.67) | 1.59‡ (1.26–2.01) | |
| 3 | Irritable bowel syndrome, postinfectious | 36 | 1.69‡ (1.41–2.01) | 2.13§ (1.42–3.18) | 2.76§ (1.52–5.02) | 1.59¶ (1.03–2.45) | 1.42§ (1.11–1.80) |
| 4 | Malaria, | 36 | 1.50‡ (1.26–1.78) | NA | 5.05‡ (2.58–9.88) | 1.05 (0.86–1.27) | 2.77§ (1.58–4.87) |
| 6 | Malaria, | 19 | 2.46‡ (1.92–3.17) | 0.83 (0.33–2.07) | 4.79‡ (2.86–8.01) | 1.14 (0.67–1.94) | 3.66‡ (2.57–5.22) |
| 8 | Fatigue >1 month (not febrile) | 18 | 3.09‡ (2.86–4.01) | 3.45§ (1.59–7.50) | 1.94 (0.86–4.37) | 1.79 (0.98–3.25) | 4.27‡ (3.01–6.05) |
| 9 | Eosinophilia | 17 | 3.34‡ (2.53–4.42) | 3.49§ (1.56–7.83) | 3.11§ (1.46–6.60) | 4.11‡ (2.46–6.84) | 2.89‡ (1.91–4.37) |
| 11 | Leishmaniasis, cutaneous | 14 | 4.89‡ (3.55–6.73) | 9.14‡ (5.15–16.24) | NA | 0.77 (0.09–6.40) | 2.30§ (1.35–3.92) |
| 12 | Schistosomiasis, human species unknown# | 13 | 4.45‡ (3.16–6.25) | 2.92 (0.18–46.68) | 3.30 (0.34–31.80) | 3.10‡ (2.09–4.59) | 7.44‡ (3.83–14.47) |
| 17 | TB, positive PPD or IGRA | 11 | 3.26‡ (2.33–4.56) | 2.92 (0.73–11.72) | 24.27‡ (8.52–69.17) | 2.44¶ (1.13–5.26) | 2.68‡ (1.71–4.18) |
| 18 | 11 | 3.33‡ (2.34–4.73) | 2.57 (0.93–7.10) | 1.52 (0.34–6.77) | 3.88‡ (1.95–7.72) | 3.52‡ (2.23–5.56) | |
| 21 | Stress | 9 | 5.70‡ (3.77–8.61) | NA | 1.65 (0.20–13.73) | 7.57‡ (3.13–18.30) | 5.55‡ (3.32–9.30) |
| 22 | Epstein-Barr virus | 8 | 2.60‡ (1.72–3.91) | 12.86‡ (3.65–45.27) | 2.99¶ (1.20–7.48) | 0.38 (0.05–2.96) | 2.29§ (1.30–4.03) |
| 25 | Strongyloidiasis, simple intestinal | 7 | 1.85§ (1.24–2.75) | 0.83 (0.17–4.01) | 3.11¶ (1.14–8.53) | 1.62 (0.88–2.99) | 1.89 (0.94–3.81) |
*Long-term travel is defined as >6 mo, short-term travel as <1 mo. NA, not applicable; TB, tuberculosis; PPD, purified protein derivative test; IGRA, interferon-gamma release assay. †Among 25 most common illnesses for all travelers. ‡p<0.0001. §p<0.01. ¶p<0.05. #Aggregated schistosomiasis diagnoses (mansoni, haematobium, japonicum, mekongi, and unknown) are grouped together and shown in Appendix Table 3,.
Comparison of rates for diagnoses among long-term and short-term travelers seen after travel by causal routes and preventive measures, GeoSentinel Surveillance Network, June 1996–December 2008*†
| Grouped diagnoses | Rate/1,000 travelers | Odds ratio (95% CI) | |
|---|---|---|---|
| Short-term travelers | Long-term travelers | ||
| Vector-borne infections | 76 | 109 | 1.47 (1.33–1.63) |
| Dengue | 24 | 17 | 0.69 (0.551–0.88) |
| Chikungunya | 2 | 2 | 1.16 (0.59–2.29) |
| Leishmaniasis | 3 | 14 | 4.89 (3.55–6.73) |
| Malaria, all species | 39 | 68 | 1.83 (1.61–2.08) |
| Rickettsiosis | 8 | 2 | 0.22 (0.11–0.45) |
| Filariasis | 2 | 5 | 3.22 (1.981–5.24) |
| Ingestion | 257 | 219 | 0.81 (0.75–0.87) |
| Enteric fever | 5 | 9 | 1.70 (1.20–2.41) |
| Hepatitis A | 2 | 3 | 1.21 (0.67–2.19) |
| Diarrhea, acute | 123 | 41 | 0.31 (0.27–0.36) |
| Diarrhea, chronic | 45 | 54 | 1.20 (1.04–1.38) |
| GI bacteria | 34 | 15 | 0.42 (0.33–0.53) |
| Giardiasis | 24 | 36 | 1.57 (1.32–1.86) |
| GI parasites | 55 | 108 | 2.08 (1.88–2.312) |
| Contact‡ | 33 | 38 | 1.15 (0.70–1.90) |
| Influenza | 8 | 5 | 0.60 (0.39–0.92) |
| Latent TB (positive PPD or IGRAs) | 4 | 11 | 3.26 (2.33–4.56) |
| Acute mononucleosis syndrome (CMV, EBV, other) | 7 | 11 | 1.60 (1.18–2.18) |
| Hepatitis B | 2 | 2 | 0.67 (0.31–1.47) |
| Hepatitis C | 1 | 2 | 1.73 (0.85–3.49) |
| Other sexually transmitted infections | 7 | 4 | 0.67 (0.43–1.05) |
| HIV (acute infection) | 2 | 1 | 0.39 (0.12–1.27) |
| Environment | 119 | 87 | 0.71 (0.63–0.79) |
| Schistosomiasis | 6 | 24 | 4.26 (3.35–5.42) |
| Strongyloides | 4 | 7 | 1.85 (1.24–2.75) |
| Hookworm | 2 | 2 | 1.26 (0.62–2.60) |
| Animal bite | 44 | 13 | 0.28 (0.22–0.37) |
| Other skin contact, noninfectious | 60 | 18 | 0.29 (0.23–0.36) |
| Fungal infection (superficial/cutaneous mycosis) | 4 | 10 | 2.33 (1.66–3.28) |
| Rash | 19 | 19 | 0.98 (0.78–1.23) |
| Psychological | 15 | 40 | 2.80 (2.35–3.33) |
| Anxiety | 3 | 4 | 1.60 (0.96–2.65) |
| Depression | 2 | 6 | 3.03 (1.89–4.86) |
| Psychosis, nonmefloquine | 1 | 2 | 3.89 (1.68–8.99) |
| Stress | 2 | 9 | 5.70 (3.77–8.61) |
| Fatigue >1 mo | 6 | 18 | 3.09 (2.86–4.01) |
| Adverse events from medication or vaccine | 7 | 3 | 0.44 (0.26–0.74) |
| Mefloquine intolerance | 4 | 1 | 0.19 (0.07–0.52) |
| Medication intolerance, nonmefloquine | 3 | 2 | 0.83 (0.44–1.56) |
*Long-term travel defined as >6 mo, short-term as <1 mo. CI, confidence interval; GI, gastrointestinal; TB, tuberculosis; PPD, purified protein derivative; IGRA, interferon-gamma release assay; CMV, cytomegalovirus; EBV, Epstein-Barr virus. †Diagnoses with proportionate illness <1/1,000 are omitted from table listing, such as hepatitis E, hepatitis delta, meningococcal meningitis, Haemophilus influenzae type b, pneumonia, pneumococcal pneumonia, varicella, chronic hepatitis, leptospirosis, altitude sickness, posttraumatic stress disorder, substance abuse, insomnia, delusional parasitosis, trauma, and violence exposure. Some patients may have >1 diagnosis. ‡Includes respiratory illnesses, blood/body fluid exchange, and sexually transmitted infections.